All In Biotech

Drug Trial Radar · NCT05482295

Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)

Immunogenicity and Safety Following In-House Recombinant Hepatitis B (Bio Farma) Vaccine Compared to Registered Hepatitis B Vaccine in Indonesian Population (Phase III)

Last checked: Nov 20, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

May 2026

Study completion May 2026

Sponsor

Lead sponsor
PT Bio FarmaIndustry
Sponsor type
Industry
Collaborators
RSUP Prof. Dr. I.G.N.G. Ngoerahal
First posted
Aug 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 10 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 3, experimental, randomized, observer-blind, lot to lot consistency study. The primary objective of this study is to assess the protectivity of In-House Recombinant Hepatitis B vaccine 28 days after 3 doses immunization.

Conditions

  • Vaccine Reaction
  • Vaccine Adverse Reaction

Interventions

  • In-House Recombinant Hepatitis B (Bio Farma) vaccineBiological

    3 doses of In-House Recombinant Hepatitis B (Bio Farma) vaccine

  • Registered Hepatitis B vaccine recombinant (Engerix-B)Biological

    3 doses of Registered Hepatitis B vaccine recombinant (Engerix-B)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ProtectivityTime frame: 28 days after the primary series of Hepatitis B vaccination

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.